nodes	percent_of_prediction	percent_of_DWPC	metapath
Mivacurium—CHRNA2—epilepsy syndrome	0.332	0.471	CbGaD
Mivacurium—CHRM3—epilepsy syndrome	0.156	0.221	CbGaD
Mivacurium—CHRM2—epilepsy syndrome	0.119	0.168	CbGaD
Mivacurium—BCHE—epilepsy syndrome	0.0989	0.14	CbGaD
Mivacurium—CHRNA1—tongue—epilepsy syndrome	0.00366	0.156	CbGeAlD
Mivacurium—Atracurium—CHRNA2—epilepsy syndrome	0.00181	0.294	CrCbGaD
Mivacurium—Cisatracurium Besylate—CHRNA2—epilepsy syndrome	0.00181	0.294	CrCbGaD
Mivacurium—Doxacurium chloride—CHRNA2—epilepsy syndrome	0.00154	0.25	CrCbGaD
Mivacurium—CHRNA2—forebrain—epilepsy syndrome	0.00129	0.055	CbGeAlD
Mivacurium—CHRNA1—head—epilepsy syndrome	0.000888	0.038	CbGeAlD
Mivacurium—CHRNB1—medulla oblongata—epilepsy syndrome	0.000865	0.037	CbGeAlD
Mivacurium—CHRNB1—midbrain—epilepsy syndrome	0.000791	0.0338	CbGeAlD
Mivacurium—CHRNB1—spinal cord—epilepsy syndrome	0.000771	0.033	CbGeAlD
Mivacurium—CHRM2—forebrain—epilepsy syndrome	0.000768	0.0328	CbGeAlD
Mivacurium—CHRNA2—head—epilepsy syndrome	0.000737	0.0315	CbGeAlD
Mivacurium—CHRM2—telencephalon—epilepsy syndrome	0.000706	0.0302	CbGeAlD
Mivacurium—CHRNA2—nervous system—epilepsy syndrome	0.000699	0.0299	CbGeAlD
Mivacurium—CHRNB1—head—epilepsy syndrome	0.000686	0.0293	CbGeAlD
Mivacurium—CHRNA2—central nervous system—epilepsy syndrome	0.000673	0.0288	CbGeAlD
Mivacurium—CHRNA2—cerebellum—epilepsy syndrome	0.000657	0.0281	CbGeAlD
Mivacurium—CHRNA1—brain—epilepsy syndrome	0.000644	0.0275	CbGeAlD
Mivacurium—CHRM3—forebrain—epilepsy syndrome	0.000625	0.0267	CbGeAlD
Mivacurium—CHRNB1—cerebellum—epilepsy syndrome	0.000612	0.0262	CbGeAlD
Mivacurium—CHRM3—telencephalon—epilepsy syndrome	0.000575	0.0246	CbGeAlD
Mivacurium—Doxacurium chloride—CHRM2—epilepsy syndrome	0.00055	0.0892	CrCbGaD
Mivacurium—CHRNA2—brain—epilepsy syndrome	0.000534	0.0228	CbGeAlD
Mivacurium—BCHE—brainstem—epilepsy syndrome	0.000529	0.0226	CbGeAlD
Mivacurium—Flushing—Propofol—epilepsy syndrome	0.00052	0.00422	CcSEcCtD
Mivacurium—Bronchospasm—Lamotrigine—epilepsy syndrome	0.000516	0.00418	CcSEcCtD
Mivacurium—Unspecified disorder of skin and subcutaneous tissue—Lacosamide—epilepsy syndrome	0.000514	0.00416	CcSEcCtD
Mivacurium—Skin disorder—Rufinamide—epilepsy syndrome	0.000513	0.00416	CcSEcCtD
Mivacurium—Bradycardia—Diazepam—epilepsy syndrome	0.000511	0.00414	CcSEcCtD
Mivacurium—BCHE—forebrain—epilepsy syndrome	0.00051	0.0218	CbGeAlD
Mivacurium—Cardiac disorder—Midazolam—epilepsy syndrome	0.000509	0.00413	CcSEcCtD
Mivacurium—Phlebitis—Pregabalin—epilepsy syndrome	0.000506	0.0041	CcSEcCtD
Mivacurium—Hypotension—Phenobarbital—epilepsy syndrome	0.000503	0.00407	CcSEcCtD
Mivacurium—Arrhythmia—Propofol—epilepsy syndrome	0.000501	0.00406	CcSEcCtD
Mivacurium—Unspecified disorder of skin and subcutaneous tissue—Clobazam—epilepsy syndrome	0.000499	0.00404	CcSEcCtD
Mivacurium—CHRNB1—brain—epilepsy syndrome	0.000497	0.0213	CbGeAlD
Mivacurium—Immune system disorder—Midazolam—epilepsy syndrome	0.000496	0.00402	CcSEcCtD
Mivacurium—Mediastinal disorder—Midazolam—epilepsy syndrome	0.000495	0.00401	CcSEcCtD
Mivacurium—Bradycardia—Felbamate—epilepsy syndrome	0.000494	0.00401	CcSEcCtD
Mivacurium—Immune system disorder—Levetiracetam—epilepsy syndrome	0.000489	0.00397	CcSEcCtD
Mivacurium—Mediastinal disorder—Levetiracetam—epilepsy syndrome	0.000488	0.00396	CcSEcCtD
Mivacurium—Erythema—Propofol—epilepsy syndrome	0.000488	0.00396	CcSEcCtD
Mivacurium—Bradycardia—Zonisamide—epilepsy syndrome	0.000484	0.00392	CcSEcCtD
Mivacurium—Skin disorder—Lacosamide—epilepsy syndrome	0.000482	0.0039	CcSEcCtD
Mivacurium—Erythema—Midazolam—epilepsy syndrome	0.000478	0.00387	CcSEcCtD
Mivacurium—Dizziness—Amobarbital—epilepsy syndrome	0.000474	0.00384	CcSEcCtD
Mivacurium—Muscle spasms—Propofol—epilepsy syndrome	0.000469	0.0038	CcSEcCtD
Mivacurium—BCHE—telencephalon—epilepsy syndrome	0.000469	0.0201	CbGeAlD
Mivacurium—Skin disorder—Clobazam—epilepsy syndrome	0.000467	0.00379	CcSEcCtD
Mivacurium—Cardiac disorder—Diazepam—epilepsy syndrome	0.000466	0.00377	CcSEcCtD
Mivacurium—Phlebitis—Gabapentin—epilepsy syndrome	0.000464	0.00376	CcSEcCtD
Mivacurium—Bradycardia—Phenytoin—epilepsy syndrome	0.000463	0.00375	CcSEcCtD
Mivacurium—Bradycardia—Oxcarbazepine—epilepsy syndrome	0.000461	0.00373	CcSEcCtD
Mivacurium—Doxacurium chloride—BCHE—epilepsy syndrome	0.000458	0.0744	CrCbGaD
Mivacurium—Dizziness—Primidone—epilepsy syndrome	0.000457	0.0037	CcSEcCtD
Mivacurium—Angiopathy—Diazepam—epilepsy syndrome	0.000455	0.00369	CcSEcCtD
Mivacurium—Rash—Amobarbital—epilepsy syndrome	0.000452	0.00366	CcSEcCtD
Mivacurium—Dermatitis—Amobarbital—epilepsy syndrome	0.000452	0.00366	CcSEcCtD
Mivacurium—Flushing—Felbamate—epilepsy syndrome	0.000451	0.00365	CcSEcCtD
Mivacurium—Anaphylactoid reaction—Pregabalin—epilepsy syndrome	0.00045	0.00365	CcSEcCtD
Mivacurium—Hypotension—Clobazam—epilepsy syndrome	0.00045	0.00364	CcSEcCtD
Mivacurium—Arrhythmia—Diazepam—epilepsy syndrome	0.000448	0.00363	CcSEcCtD
Mivacurium—Bradycardia—Carbamazepine—epilepsy syndrome	0.000442	0.00358	CcSEcCtD
Mivacurium—CHRM2—head—epilepsy syndrome	0.000439	0.0188	CbGeAlD
Mivacurium—Muscle spasms—Fosphenytoin—epilepsy syndrome	0.000438	0.00355	CcSEcCtD
Mivacurium—Erythema—Diazepam—epilepsy syndrome	0.000437	0.00354	CcSEcCtD
Mivacurium—Rash—Primidone—epilepsy syndrome	0.000435	0.00353	CcSEcCtD
Mivacurium—Dermatitis—Primidone—epilepsy syndrome	0.000435	0.00352	CcSEcCtD
Mivacurium—Immune system disorder—Zonisamide—epilepsy syndrome	0.000429	0.00348	CcSEcCtD
Mivacurium—Anaphylactic shock—Acetazolamide—epilepsy syndrome	0.000429	0.00348	CcSEcCtD
Mivacurium—Mediastinal disorder—Zonisamide—epilepsy syndrome	0.000428	0.00347	CcSEcCtD
Mivacurium—Urticaria—Phenobarbital—epilepsy syndrome	0.000427	0.00346	CcSEcCtD
Mivacurium—Muscle spasms—Vigabatrin—epilepsy syndrome	0.000427	0.00346	CcSEcCtD
Mivacurium—Flushing—Clonazepam—epilepsy syndrome	0.000425	0.00345	CcSEcCtD
Mivacurium—Cardiac disorder—Clonazepam—epilepsy syndrome	0.000425	0.00345	CcSEcCtD
Mivacurium—Flushing—Oxcarbazepine—epilepsy syndrome	0.00042	0.0034	CcSEcCtD
Mivacurium—Cardiac disorder—Oxcarbazepine—epilepsy syndrome	0.00042	0.0034	CcSEcCtD
Mivacurium—Muscle spasms—Diazepam—epilepsy syndrome	0.00042	0.0034	CcSEcCtD
Mivacurium—CHRM2—nervous system—epilepsy syndrome	0.000417	0.0178	CbGeAlD
Mivacurium—Immune system disorder—Clonazepam—epilepsy syndrome	0.000414	0.00335	CcSEcCtD
Mivacurium—Immune system disorder—Phenytoin—epilepsy syndrome	0.000411	0.00333	CcSEcCtD
Mivacurium—Angiopathy—Oxcarbazepine—epilepsy syndrome	0.000411	0.00333	CcSEcCtD
Mivacurium—Immune system disorder—Oxcarbazepine—epilepsy syndrome	0.000409	0.00331	CcSEcCtD
Mivacurium—Arrhythmia—Oxcarbazepine—epilepsy syndrome	0.000404	0.00328	CcSEcCtD
Mivacurium—Unspecified disorder of skin and subcutaneous tissue—Midazolam—epilepsy syndrome	0.000404	0.00327	CcSEcCtD
Mivacurium—Cardiac disorder—Carbamazepine—epilepsy syndrome	0.000403	0.00327	CcSEcCtD
Mivacurium—Flushing—Carbamazepine—epilepsy syndrome	0.000403	0.00327	CcSEcCtD
Mivacurium—CHRM2—central nervous system—epilepsy syndrome	0.000401	0.0172	CbGeAlD
Mivacurium—Unspecified disorder of skin and subcutaneous tissue—Levetiracetam—epilepsy syndrome	0.000399	0.00323	CcSEcCtD
Mivacurium—Anaphylactic shock—Propofol—epilepsy syndrome	0.000398	0.00323	CcSEcCtD
Mivacurium—Muscle spasms—Zonisamide—epilepsy syndrome	0.000398	0.00322	CcSEcCtD
Mivacurium—Angiopathy—Carbamazepine—epilepsy syndrome	0.000394	0.00319	CcSEcCtD
Mivacurium—Urticaria—Lacosamide—epilepsy syndrome	0.000394	0.00319	CcSEcCtD
Mivacurium—Immune system disorder—Carbamazepine—epilepsy syndrome	0.000392	0.00318	CcSEcCtD
Mivacurium—Mediastinal disorder—Carbamazepine—epilepsy syndrome	0.000392	0.00317	CcSEcCtD
Mivacurium—Phlebitis—Topiramate—epilepsy syndrome	0.00039	0.00316	CcSEcCtD
Mivacurium—Anaphylactic shock—Midazolam—epilepsy syndrome	0.00039	0.00316	CcSEcCtD
Mivacurium—Flushing—Lamotrigine—epilepsy syndrome	0.00039	0.00316	CcSEcCtD
Mivacurium—Tachycardia—Propofol—epilepsy syndrome	0.000389	0.00315	CcSEcCtD
Mivacurium—Arrhythmia—Carbamazepine—epilepsy syndrome	0.000388	0.00314	CcSEcCtD
Mivacurium—Muscle spasms—Clonazepam—epilepsy syndrome	0.000383	0.00311	CcSEcCtD
Mivacurium—Rash—Trimethadione—epilepsy syndrome	0.000383	0.0031	CcSEcCtD
Mivacurium—Dermatitis—Trimethadione—epilepsy syndrome	0.000383	0.0031	CcSEcCtD
Mivacurium—Urticaria—Clobazam—epilepsy syndrome	0.000382	0.0031	CcSEcCtD
Mivacurium—Angiopathy—Lamotrigine—epilepsy syndrome	0.000381	0.00309	CcSEcCtD
Mivacurium—Muscle spasms—Phenytoin—epilepsy syndrome	0.000381	0.00309	CcSEcCtD
Mivacurium—Tachycardia—Midazolam—epilepsy syndrome	0.00038	0.00308	CcSEcCtD
Mivacurium—Skin disorder—Midazolam—epilepsy syndrome	0.000379	0.00307	CcSEcCtD
Mivacurium—Mediastinal disorder—Lamotrigine—epilepsy syndrome	0.000378	0.00307	CcSEcCtD
Mivacurium—Erythema—Carbamazepine—epilepsy syndrome	0.000378	0.00306	CcSEcCtD
Mivacurium—Unspecified disorder of skin and subcutaneous tissue—Vigabatrin—epilepsy syndrome	0.000375	0.00304	CcSEcCtD
Mivacurium—Skin disorder—Levetiracetam—epilepsy syndrome	0.000374	0.00303	CcSEcCtD
Mivacurium—Hypotension—Propofol—epilepsy syndrome	0.000372	0.00302	CcSEcCtD
Mivacurium—Anaphylactic shock—Fosphenytoin—epilepsy syndrome	0.000372	0.00301	CcSEcCtD
Mivacurium—Unspecified disorder of skin and subcutaneous tissue—Diazepam—epilepsy syndrome	0.000369	0.00299	CcSEcCtD
Mivacurium—BCHE—medulla oblongata—epilepsy syndrome	0.000369	0.0158	CbGeAlD
Mivacurium—Erythema—Lamotrigine—epilepsy syndrome	0.000366	0.00296	CcSEcCtD
Mivacurium—Hypotension—Midazolam—epilepsy syndrome	0.000364	0.00295	CcSEcCtD
Mivacurium—Muscle spasms—Carbamazepine—epilepsy syndrome	0.000364	0.00295	CcSEcCtD
Mivacurium—Tachycardia—Fosphenytoin—epilepsy syndrome	0.000363	0.00294	CcSEcCtD
Mivacurium—CHRM3—head—epilepsy syndrome	0.000358	0.0153	CbGeAlD
Mivacurium—Anaphylactic shock—Diazepam—epilepsy syndrome	0.000357	0.00289	CcSEcCtD
Mivacurium—Dizziness—Phenobarbital—epilepsy syndrome	0.000356	0.00288	CcSEcCtD
Mivacurium—Skin disorder—Vigabatrin—epilepsy syndrome	0.000352	0.00285	CcSEcCtD
Mivacurium—Muscle spasms—Lamotrigine—epilepsy syndrome	0.000351	0.00285	CcSEcCtD
Mivacurium—Unspecified disorder of skin and subcutaneous tissue—Zonisamide—epilepsy syndrome	0.00035	0.00284	CcSEcCtD
Mivacurium—Dizziness—Rufinamide—epilepsy syndrome	0.000349	0.00283	CcSEcCtD
Mivacurium—Tachycardia—Diazepam—epilepsy syndrome	0.000348	0.00282	CcSEcCtD
Mivacurium—Hypotension—Fosphenytoin—epilepsy syndrome	0.000347	0.00281	CcSEcCtD
Mivacurium—Skin disorder—Diazepam—epilepsy syndrome	0.000346	0.00281	CcSEcCtD
Mivacurium—Anaphylactic shock—Felbamate—epilepsy syndrome	0.000345	0.0028	CcSEcCtD
Mivacurium—Urticaria—Acetazolamide—epilepsy syndrome	0.000341	0.00276	CcSEcCtD
Mivacurium—Bronchospasm—Gabapentin—epilepsy syndrome	0.00034	0.00275	CcSEcCtD
Mivacurium—Bradycardia—Valproic Acid—epilepsy syndrome	0.00034	0.00275	CcSEcCtD
Mivacurium—CHRM3—nervous system—epilepsy syndrome	0.000339	0.0145	CbGeAlD
Mivacurium—Rash—Phenobarbital—epilepsy syndrome	0.000339	0.00275	CcSEcCtD
Mivacurium—Dermatitis—Phenobarbital—epilepsy syndrome	0.000339	0.00275	CcSEcCtD
Mivacurium—Unspecified disorder of skin and subcutaneous tissue—Clonazepam—epilepsy syndrome	0.000337	0.00273	CcSEcCtD
Mivacurium—BCHE—midbrain—epilepsy syndrome	0.000337	0.0144	CbGeAlD
Mivacurium—Tachycardia—Felbamate—epilepsy syndrome	0.000337	0.00273	CcSEcCtD
Mivacurium—Unspecified disorder of skin and subcutaneous tissue—Oxcarbazepine—epilepsy syndrome	0.000333	0.0027	CcSEcCtD
Mivacurium—Hypotension—Diazepam—epilepsy syndrome	0.000333	0.0027	CcSEcCtD
Mivacurium—Rash—Rufinamide—epilepsy syndrome	0.000333	0.0027	CcSEcCtD
Mivacurium—Dermatitis—Rufinamide—epilepsy syndrome	0.000333	0.0027	CcSEcCtD
Mivacurium—Tachycardia—Zonisamide—epilepsy syndrome	0.00033	0.00267	CcSEcCtD
Mivacurium—BCHE—spinal cord—epilepsy syndrome	0.000329	0.0141	CbGeAlD
Mivacurium—Skin disorder—Zonisamide—epilepsy syndrome	0.000328	0.00266	CcSEcCtD
Mivacurium—Dizziness—Lacosamide—epilepsy syndrome	0.000328	0.00266	CcSEcCtD
Mivacurium—CHRM3—central nervous system—epilepsy syndrome	0.000327	0.014	CbGeAlD
Mivacurium—Anaphylactic shock—Clonazepam—epilepsy syndrome	0.000326	0.00264	CcSEcCtD
Mivacurium—Anaphylactic shock—Phenytoin—epilepsy syndrome	0.000323	0.00262	CcSEcCtD
Mivacurium—Hypotension—Felbamate—epilepsy syndrome	0.000322	0.00261	CcSEcCtD
Mivacurium—Anaphylactic shock—Oxcarbazepine—epilepsy syndrome	0.000322	0.00261	CcSEcCtD
Mivacurium—Unspecified disorder of skin and subcutaneous tissue—Carbamazepine—epilepsy syndrome	0.00032	0.00259	CcSEcCtD
Mivacurium—CHRM2—brain—epilepsy syndrome	0.000318	0.0136	CbGeAlD
Mivacurium—Dizziness—Clobazam—epilepsy syndrome	0.000318	0.00258	CcSEcCtD
Mivacurium—Tachycardia—Clonazepam—epilepsy syndrome	0.000318	0.00257	CcSEcCtD
Mivacurium—Urticaria—Propofol—epilepsy syndrome	0.000317	0.00256	CcSEcCtD
Mivacurium—Skin disorder—Clonazepam—epilepsy syndrome	0.000316	0.00256	CcSEcCtD
Mivacurium—Hypotension—Zonisamide—epilepsy syndrome	0.000316	0.00256	CcSEcCtD
Mivacurium—Tachycardia—Phenytoin—epilepsy syndrome	0.000316	0.00256	CcSEcCtD
Mivacurium—Tachycardia—Oxcarbazepine—epilepsy syndrome	0.000314	0.00254	CcSEcCtD
Mivacurium—Rash—Lacosamide—epilepsy syndrome	0.000313	0.00253	CcSEcCtD
Mivacurium—Skin disorder—Oxcarbazepine—epilepsy syndrome	0.000312	0.00253	CcSEcCtD
Mivacurium—Dermatitis—Lacosamide—epilepsy syndrome	0.000312	0.00253	CcSEcCtD
Mivacurium—Urticaria—Midazolam—epilepsy syndrome	0.00031	0.00251	CcSEcCtD
Mivacurium—Anaphylactic shock—Carbamazepine—epilepsy syndrome	0.000309	0.0025	CcSEcCtD
Mivacurium—Bradycardia—Pregabalin—epilepsy syndrome	0.000307	0.00249	CcSEcCtD
Mivacurium—Hypotension—Clonazepam—epilepsy syndrome	0.000304	0.00246	CcSEcCtD
Mivacurium—Rash—Clobazam—epilepsy syndrome	0.000303	0.00246	CcSEcCtD
Mivacurium—Dermatitis—Clobazam—epilepsy syndrome	0.000303	0.00246	CcSEcCtD
Mivacurium—Angiopathy—Valproic Acid—epilepsy syndrome	0.000303	0.00245	CcSEcCtD
Mivacurium—Hypotension—Phenytoin—epilepsy syndrome	0.000302	0.00245	CcSEcCtD
Mivacurium—Immune system disorder—Valproic Acid—epilepsy syndrome	0.000301	0.00244	CcSEcCtD
Mivacurium—Tachycardia—Carbamazepine—epilepsy syndrome	0.000301	0.00244	CcSEcCtD
Mivacurium—Mediastinal disorder—Valproic Acid—epilepsy syndrome	0.000301	0.00244	CcSEcCtD
Mivacurium—Hypotension—Oxcarbazepine—epilepsy syndrome	0.000301	0.00244	CcSEcCtD
Mivacurium—Skin disorder—Carbamazepine—epilepsy syndrome	0.0003	0.00243	CcSEcCtD
Mivacurium—Arrhythmia—Valproic Acid—epilepsy syndrome	0.000298	0.00241	CcSEcCtD
Mivacurium—Urticaria—Fosphenytoin—epilepsy syndrome	0.000295	0.00239	CcSEcCtD
Mivacurium—BCHE—head—epilepsy syndrome	0.000292	0.0125	CbGeAlD
Mivacurium—Tachycardia—Lamotrigine—epilepsy syndrome	0.000291	0.00236	CcSEcCtD
Mivacurium—Hypotension—Carbamazepine—epilepsy syndrome	0.000288	0.00234	CcSEcCtD
Mivacurium—Urticaria—Vigabatrin—epilepsy syndrome	0.000288	0.00233	CcSEcCtD
Mivacurium—Dizziness—Acetazolamide—epilepsy syndrome	0.000284	0.0023	CcSEcCtD
Mivacurium—Urticaria—Diazepam—epilepsy syndrome	0.000283	0.00229	CcSEcCtD
Mivacurium—Bradycardia—Gabapentin—epilepsy syndrome	0.000282	0.00228	CcSEcCtD
Mivacurium—Cardiac disorder—Pregabalin—epilepsy syndrome	0.00028	0.00227	CcSEcCtD
Mivacurium—Flushing—Pregabalin—epilepsy syndrome	0.00028	0.00227	CcSEcCtD
Mivacurium—Muscle spasms—Valproic Acid—epilepsy syndrome	0.000279	0.00226	CcSEcCtD
Mivacurium—BCHE—nervous system—epilepsy syndrome	0.000277	0.0118	CbGeAlD
Mivacurium—Urticaria—Felbamate—epilepsy syndrome	0.000274	0.00222	CcSEcCtD
Mivacurium—Angiopathy—Pregabalin—epilepsy syndrome	0.000274	0.00222	CcSEcCtD
Mivacurium—Immune system disorder—Pregabalin—epilepsy syndrome	0.000272	0.00221	CcSEcCtD
Mivacurium—Mediastinal disorder—Pregabalin—epilepsy syndrome	0.000272	0.0022	CcSEcCtD
Mivacurium—Arrhythmia—Pregabalin—epilepsy syndrome	0.000269	0.00218	CcSEcCtD
Mivacurium—Urticaria—Zonisamide—epilepsy syndrome	0.000268	0.00217	CcSEcCtD
Mivacurium—BCHE—central nervous system—epilepsy syndrome	0.000267	0.0114	CbGeAlD
Mivacurium—Dizziness—Propofol—epilepsy syndrome	0.000263	0.00213	CcSEcCtD
Mivacurium—BCHE—cerebellum—epilepsy syndrome	0.000261	0.0111	CbGeAlD
Mivacurium—CHRM3—brain—epilepsy syndrome	0.000259	0.0111	CbGeAlD
Mivacurium—Urticaria—Clonazepam—epilepsy syndrome	0.000259	0.0021	CcSEcCtD
Mivacurium—Dizziness—Midazolam—epilepsy syndrome	0.000258	0.00209	CcSEcCtD
Mivacurium—Urticaria—Phenytoin—epilepsy syndrome	0.000257	0.00208	CcSEcCtD
Mivacurium—Cardiac disorder—Gabapentin—epilepsy syndrome	0.000257	0.00208	CcSEcCtD
Mivacurium—Urticaria—Oxcarbazepine—epilepsy syndrome	0.000256	0.00207	CcSEcCtD
Mivacurium—Dizziness—Levetiracetam—epilepsy syndrome	0.000255	0.00206	CcSEcCtD
Mivacurium—Muscle spasms—Pregabalin—epilepsy syndrome	0.000252	0.00205	CcSEcCtD
Mivacurium—Rash—Propofol—epilepsy syndrome	0.000251	0.00204	CcSEcCtD
Mivacurium—Dermatitis—Propofol—epilepsy syndrome	0.000251	0.00203	CcSEcCtD
Mivacurium—Immune system disorder—Gabapentin—epilepsy syndrome	0.00025	0.00202	CcSEcCtD
Mivacurium—Mediastinal disorder—Gabapentin—epilepsy syndrome	0.000249	0.00202	CcSEcCtD
Mivacurium—Rash—Midazolam—epilepsy syndrome	0.000246	0.00199	CcSEcCtD
Mivacurium—Dizziness—Fosphenytoin—epilepsy syndrome	0.000246	0.00199	CcSEcCtD
Mivacurium—Unspecified disorder of skin and subcutaneous tissue—Valproic Acid—epilepsy syndrome	0.000246	0.00199	CcSEcCtD
Mivacurium—Dermatitis—Midazolam—epilepsy syndrome	0.000246	0.00199	CcSEcCtD
Mivacurium—Urticaria—Carbamazepine—epilepsy syndrome	0.000245	0.00199	CcSEcCtD
Mivacurium—Rash—Levetiracetam—epilepsy syndrome	0.000243	0.00197	CcSEcCtD
Mivacurium—Dermatitis—Levetiracetam—epilepsy syndrome	0.000242	0.00196	CcSEcCtD
Mivacurium—Erythema—Gabapentin—epilepsy syndrome	0.000241	0.00195	CcSEcCtD
Mivacurium—Dizziness—Vigabatrin—epilepsy syndrome	0.000239	0.00194	CcSEcCtD
Mivacurium—Anaphylactic shock—Valproic Acid—epilepsy syndrome	0.000237	0.00192	CcSEcCtD
Mivacurium—Urticaria—Lamotrigine—epilepsy syndrome	0.000237	0.00192	CcSEcCtD
Mivacurium—Bradycardia—Topiramate—epilepsy syndrome	0.000237	0.00192	CcSEcCtD
Mivacurium—Dizziness—Diazepam—epilepsy syndrome	0.000236	0.00191	CcSEcCtD
Mivacurium—Rash—Fosphenytoin—epilepsy syndrome	0.000234	0.0019	CcSEcCtD
Mivacurium—Dermatitis—Fosphenytoin—epilepsy syndrome	0.000234	0.0019	CcSEcCtD
Mivacurium—Muscle spasms—Gabapentin—epilepsy syndrome	0.000231	0.00188	CcSEcCtD
Mivacurium—Tachycardia—Valproic Acid—epilepsy syndrome	0.000231	0.00187	CcSEcCtD
Mivacurium—Skin disorder—Valproic Acid—epilepsy syndrome	0.00023	0.00187	CcSEcCtD
Mivacurium—Rash—Vigabatrin—epilepsy syndrome	0.000228	0.00185	CcSEcCtD
Mivacurium—Dizziness—Felbamate—epilepsy syndrome	0.000228	0.00185	CcSEcCtD
Mivacurium—Dermatitis—Vigabatrin—epilepsy syndrome	0.000228	0.00185	CcSEcCtD
Mivacurium—Rash—Diazepam—epilepsy syndrome	0.000225	0.00182	CcSEcCtD
Mivacurium—Dermatitis—Diazepam—epilepsy syndrome	0.000225	0.00182	CcSEcCtD
Mivacurium—Dizziness—Zonisamide—epilepsy syndrome	0.000223	0.00181	CcSEcCtD
Mivacurium—Unspecified disorder of skin and subcutaneous tissue—Pregabalin—epilepsy syndrome	0.000222	0.0018	CcSEcCtD
Mivacurium—Hypotension—Valproic Acid—epilepsy syndrome	0.000222	0.00179	CcSEcCtD
Mivacurium—Rash—Felbamate—epilepsy syndrome	0.000218	0.00176	CcSEcCtD
Mivacurium—Dermatitis—Felbamate—epilepsy syndrome	0.000217	0.00176	CcSEcCtD
Mivacurium—Cardiac disorder—Topiramate—epilepsy syndrome	0.000216	0.00175	CcSEcCtD
Mivacurium—Flushing—Topiramate—epilepsy syndrome	0.000216	0.00175	CcSEcCtD
Mivacurium—Dizziness—Clonazepam—epilepsy syndrome	0.000215	0.00174	CcSEcCtD
Mivacurium—Anaphylactic shock—Pregabalin—epilepsy syndrome	0.000214	0.00174	CcSEcCtD
Mivacurium—Dizziness—Phenytoin—epilepsy syndrome	0.000214	0.00173	CcSEcCtD
Mivacurium—Rash—Zonisamide—epilepsy syndrome	0.000213	0.00173	CcSEcCtD
Mivacurium—Dermatitis—Zonisamide—epilepsy syndrome	0.000213	0.00172	CcSEcCtD
Mivacurium—Dizziness—Oxcarbazepine—epilepsy syndrome	0.000213	0.00172	CcSEcCtD
Mivacurium—BCHE—brain—epilepsy syndrome	0.000212	0.00906	CbGeAlD
Mivacurium—Angiopathy—Topiramate—epilepsy syndrome	0.000211	0.00171	CcSEcCtD
Mivacurium—Immune system disorder—Topiramate—epilepsy syndrome	0.00021	0.0017	CcSEcCtD
Mivacurium—Mediastinal disorder—Topiramate—epilepsy syndrome	0.00021	0.0017	CcSEcCtD
Mivacurium—Tachycardia—Pregabalin—epilepsy syndrome	0.000209	0.00169	CcSEcCtD
Mivacurium—Skin disorder—Pregabalin—epilepsy syndrome	0.000208	0.00169	CcSEcCtD
Mivacurium—Rash—Clonazepam—epilepsy syndrome	0.000205	0.00166	CcSEcCtD
Mivacurium—Dermatitis—Clonazepam—epilepsy syndrome	0.000205	0.00166	CcSEcCtD
Mivacurium—Dizziness—Carbamazepine—epilepsy syndrome	0.000204	0.00165	CcSEcCtD
Mivacurium—Rash—Phenytoin—epilepsy syndrome	0.000204	0.00165	CcSEcCtD
Mivacurium—Dermatitis—Phenytoin—epilepsy syndrome	0.000204	0.00165	CcSEcCtD
Mivacurium—Unspecified disorder of skin and subcutaneous tissue—Gabapentin—epilepsy syndrome	0.000204	0.00165	CcSEcCtD
Mivacurium—Rash—Oxcarbazepine—epilepsy syndrome	0.000203	0.00164	CcSEcCtD
Mivacurium—Dermatitis—Oxcarbazepine—epilepsy syndrome	0.000203	0.00164	CcSEcCtD
Mivacurium—Erythema—Topiramate—epilepsy syndrome	0.000203	0.00164	CcSEcCtD
Mivacurium—Hypotension—Pregabalin—epilepsy syndrome	0.0002	0.00162	CcSEcCtD
Mivacurium—Dizziness—Lamotrigine—epilepsy syndrome	0.000197	0.0016	CcSEcCtD
Mivacurium—Anaphylactic shock—Gabapentin—epilepsy syndrome	0.000197	0.00159	CcSEcCtD
Mivacurium—Muscle spasms—Topiramate—epilepsy syndrome	0.000195	0.00158	CcSEcCtD
Mivacurium—Rash—Carbamazepine—epilepsy syndrome	0.000195	0.00158	CcSEcCtD
Mivacurium—Dermatitis—Carbamazepine—epilepsy syndrome	0.000194	0.00158	CcSEcCtD
Mivacurium—Tachycardia—Gabapentin—epilepsy syndrome	0.000192	0.00155	CcSEcCtD
Mivacurium—Skin disorder—Gabapentin—epilepsy syndrome	0.000191	0.00155	CcSEcCtD
Mivacurium—Urticaria—Valproic Acid—epilepsy syndrome	0.000188	0.00153	CcSEcCtD
Mivacurium—Rash—Lamotrigine—epilepsy syndrome	0.000188	0.00152	CcSEcCtD
Mivacurium—Dermatitis—Lamotrigine—epilepsy syndrome	0.000188	0.00152	CcSEcCtD
Mivacurium—Hypotension—Gabapentin—epilepsy syndrome	0.000184	0.00149	CcSEcCtD
Mivacurium—Unspecified disorder of skin and subcutaneous tissue—Topiramate—epilepsy syndrome	0.000171	0.00139	CcSEcCtD
Mivacurium—Urticaria—Pregabalin—epilepsy syndrome	0.00017	0.00138	CcSEcCtD
Mivacurium—Tachycardia—Topiramate—epilepsy syndrome	0.000161	0.00131	CcSEcCtD
Mivacurium—Skin disorder—Topiramate—epilepsy syndrome	0.000161	0.0013	CcSEcCtD
Mivacurium—Dizziness—Valproic Acid—epilepsy syndrome	0.000157	0.00127	CcSEcCtD
Mivacurium—Urticaria—Gabapentin—epilepsy syndrome	0.000156	0.00126	CcSEcCtD
Mivacurium—Hypotension—Topiramate—epilepsy syndrome	0.000154	0.00125	CcSEcCtD
Mivacurium—Rash—Valproic Acid—epilepsy syndrome	0.000149	0.00121	CcSEcCtD
Mivacurium—Dermatitis—Valproic Acid—epilepsy syndrome	0.000149	0.00121	CcSEcCtD
Mivacurium—Dizziness—Pregabalin—epilepsy syndrome	0.000142	0.00115	CcSEcCtD
Mivacurium—Rash—Pregabalin—epilepsy syndrome	0.000135	0.00109	CcSEcCtD
Mivacurium—Dermatitis—Pregabalin—epilepsy syndrome	0.000135	0.00109	CcSEcCtD
Mivacurium—Urticaria—Topiramate—epilepsy syndrome	0.000131	0.00106	CcSEcCtD
Mivacurium—Dizziness—Gabapentin—epilepsy syndrome	0.00013	0.00105	CcSEcCtD
Mivacurium—Rash—Gabapentin—epilepsy syndrome	0.000124	0.001	CcSEcCtD
Mivacurium—Dermatitis—Gabapentin—epilepsy syndrome	0.000124	0.001	CcSEcCtD
Mivacurium—Dizziness—Topiramate—epilepsy syndrome	0.000109	0.000886	CcSEcCtD
Mivacurium—Rash—Topiramate—epilepsy syndrome	0.000104	0.000845	CcSEcCtD
Mivacurium—Dermatitis—Topiramate—epilepsy syndrome	0.000104	0.000844	CcSEcCtD
Mivacurium—CHRM2—GPCR downstream signaling—CNR1—epilepsy syndrome	9.13e-06	6.41e-05	CbGpPWpGaD
Mivacurium—CHRM2—GPCR downstream signaling—PLCB1—epilepsy syndrome	9.1e-06	6.39e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—GRM8—epilepsy syndrome	9.09e-06	6.39e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—PGF—epilepsy syndrome	9.09e-06	6.39e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—SST—epilepsy syndrome	9.07e-06	6.37e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—CCR2—epilepsy syndrome	9.07e-06	6.37e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—PGF—epilepsy syndrome	9e-06	6.32e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—GRM8—epilepsy syndrome	9e-06	6.32e-05	CbGpPWpGaD
Mivacurium—CHRM3—GPCR downstream signaling—HTR7—epilepsy syndrome	8.99e-06	6.32e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—SST—epilepsy syndrome	8.98e-06	6.31e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—CCR2—epilepsy syndrome	8.98e-06	6.31e-05	CbGpPWpGaD
Mivacurium—CHRM2—GPCR downstream signaling—HTR7—epilepsy syndrome	8.91e-06	6.26e-05	CbGpPWpGaD
Mivacurium—CHRM3—GPCR ligand binding—POMC—epilepsy syndrome	8.9e-06	6.25e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—ADRA2A—epilepsy syndrome	8.88e-06	6.24e-05	CbGpPWpGaD
Mivacurium—CHRM2—GPCR ligand binding—POMC—epilepsy syndrome	8.81e-06	6.19e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—ADRA2A—epilepsy syndrome	8.79e-06	6.18e-05	CbGpPWpGaD
Mivacurium—CHRM3—GPCR ligand binding—CCL2—epilepsy syndrome	8.71e-06	6.12e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—GNAO1—epilepsy syndrome	8.67e-06	6.09e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—OPRD1—epilepsy syndrome	8.67e-06	6.09e-05	CbGpPWpGaD
Mivacurium—CHRM2—GPCR ligand binding—CCL2—epilepsy syndrome	8.62e-06	6.06e-05	CbGpPWpGaD
Mivacurium—BCHE—Metabolism of lipids and lipoproteins—ALB—epilepsy syndrome	8.59e-06	6.04e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—GNAO1—epilepsy syndrome	8.59e-06	6.03e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—OPRD1—epilepsy syndrome	8.59e-06	6.03e-05	CbGpPWpGaD
Mivacurium—CHRM3—GPCR downstream signaling—AKT3—epilepsy syndrome	8.57e-06	6.02e-05	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—CYP2D6—epilepsy syndrome	8.57e-06	6.02e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—BDKRB2—epilepsy syndrome	8.53e-06	5.99e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—CXCL12—epilepsy syndrome	8.53e-06	5.99e-05	CbGpPWpGaD
Mivacurium—CHRM2—GPCR downstream signaling—AKT3—epilepsy syndrome	8.49e-06	5.96e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—BDKRB2—epilepsy syndrome	8.44e-06	5.93e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—CXCL12—epilepsy syndrome	8.44e-06	5.93e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—CNR1—epilepsy syndrome	8.37e-06	5.88e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—PLCB1—epilepsy syndrome	8.34e-06	5.86e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—GRM1—epilepsy syndrome	8.31e-06	5.84e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—PDYN—epilepsy syndrome	8.31e-06	5.84e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—CCR7—epilepsy syndrome	8.31e-06	5.84e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—CHRM1—epilepsy syndrome	8.31e-06	5.84e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—CNR1—epilepsy syndrome	8.29e-06	5.82e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—PLCB1—epilepsy syndrome	8.26e-06	5.8e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—CHRM1—epilepsy syndrome	8.23e-06	5.78e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—PDYN—epilepsy syndrome	8.23e-06	5.78e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—CCR7—epilepsy syndrome	8.23e-06	5.78e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—GRM1—epilepsy syndrome	8.23e-06	5.78e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—HTR7—epilepsy syndrome	8.17e-06	5.74e-05	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—ADRA2A—epilepsy syndrome	8.15e-06	5.73e-05	CbGpPWpGaD
Mivacurium—BCHE—Metabolism of proteins—POMC—epilepsy syndrome	8.14e-06	5.72e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—HTR7—epilepsy syndrome	8.09e-06	5.68e-05	CbGpPWpGaD
Mivacurium—BCHE—Metabolism of proteins—CCL2—epilepsy syndrome	7.97e-06	5.6e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—HBEGF—epilepsy syndrome	7.93e-06	5.57e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—HBEGF—epilepsy syndrome	7.85e-06	5.52e-05	CbGpPWpGaD
Mivacurium—CHRM3—GPCR downstream signaling—CDC42—epilepsy syndrome	7.82e-06	5.49e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—GAL—epilepsy syndrome	7.82e-06	5.49e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—GFAP—epilepsy syndrome	7.82e-06	5.49e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—AKT3—epilepsy syndrome	7.78e-06	5.47e-05	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—SLC2A1—epilepsy syndrome	7.75e-06	5.44e-05	CbGpPWpGaD
Mivacurium—CHRM2—GPCR downstream signaling—CDC42—epilepsy syndrome	7.74e-06	5.44e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—GAL—epilepsy syndrome	7.74e-06	5.44e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—GFAP—epilepsy syndrome	7.74e-06	5.44e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—GRM5—epilepsy syndrome	7.73e-06	5.43e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—CASP2—epilepsy syndrome	7.73e-06	5.43e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—AKT3—epilepsy syndrome	7.71e-06	5.41e-05	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—PLCB1—epilepsy syndrome	7.66e-06	5.38e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—GRM5—epilepsy syndrome	7.65e-06	5.38e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—CASP2—epilepsy syndrome	7.65e-06	5.38e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—CHRM3—epilepsy syndrome	7.65e-06	5.38e-05	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—TH—epilepsy syndrome	7.63e-06	5.36e-05	CbGpPWpGaD
Mivacurium—CHRM3—GPCR downstream signaling—AVP—epilepsy syndrome	7.57e-06	5.32e-05	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—ABCG2—epilepsy syndrome	7.54e-06	5.29e-05	CbGpPWpGaD
Mivacurium—BCHE—Metabolism of lipids and lipoproteins—PTGS2—epilepsy syndrome	7.52e-06	5.28e-05	CbGpPWpGaD
Mivacurium—CHRM2—GPCR downstream signaling—AVP—epilepsy syndrome	7.5e-06	5.27e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—CX3CR1—epilepsy syndrome	7.41e-06	5.21e-05	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—CYP2C19—epilepsy syndrome	7.34e-06	5.16e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—CX3CR1—epilepsy syndrome	7.34e-06	5.16e-05	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—CYP11A1—epilepsy syndrome	7.3e-06	5.13e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—CX3CL1—epilepsy syndrome	7.27e-06	5.11e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—BDKRB1—epilepsy syndrome	7.27e-06	5.11e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—CHRM2—epilepsy syndrome	7.27e-06	5.11e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—BDKRB1—epilepsy syndrome	7.2e-06	5.06e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—CX3CL1—epilepsy syndrome	7.2e-06	5.06e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—CDC42—epilepsy syndrome	7.1e-06	4.99e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—GABBR1—epilepsy syndrome	7.07e-06	4.97e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—CDC42—epilepsy syndrome	7.03e-06	4.94e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—GABBR1—epilepsy syndrome	7e-06	4.92e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—AVP—epilepsy syndrome	6.87e-06	4.83e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—AVP—epilepsy syndrome	6.81e-06	4.78e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—HRH3—epilepsy syndrome	6.78e-06	4.76e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—HRH3—epilepsy syndrome	6.71e-06	4.72e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—OPRM1—epilepsy syndrome	6.67e-06	4.69e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—OPRM1—epilepsy syndrome	6.61e-06	4.64e-05	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—CYP2D6—epilepsy syndrome	6.59e-06	4.63e-05	CbGpPWpGaD
Mivacurium—CHRM3—GPCR downstream signaling—CCR5—epilepsy syndrome	6.44e-06	4.52e-05	CbGpPWpGaD
Mivacurium—CHRM2—GPCR downstream signaling—CCR5—epilepsy syndrome	6.37e-06	4.48e-05	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—HMOX1—epilepsy syndrome	6.37e-06	4.48e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—CCR3—epilepsy syndrome	6.3e-06	4.43e-05	CbGpPWpGaD
Mivacurium—CHRM3—GPCR downstream signaling—HTR2A—epilepsy syndrome	6.3e-06	4.42e-05	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—CAT—epilepsy syndrome	6.29e-06	4.42e-05	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—ADRA2A—epilepsy syndrome	6.27e-06	4.41e-05	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—BCHE—epilepsy syndrome	6.24e-06	4.39e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—CCR3—epilepsy syndrome	6.24e-06	4.38e-05	CbGpPWpGaD
Mivacurium—CHRM2—GPCR downstream signaling—HTR2A—epilepsy syndrome	6.24e-06	4.38e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—NPY—epilepsy syndrome	6.14e-06	4.31e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—ATP2A2—epilepsy syndrome	6.14e-06	4.31e-05	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—ABCB1—epilepsy syndrome	6.12e-06	4.3e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—NPY—epilepsy syndrome	6.08e-06	4.27e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—ATP2A2—epilepsy syndrome	6.08e-06	4.27e-05	CbGpPWpGaD
Mivacurium—CHRM3—GPCR downstream signaling—AGT—epilepsy syndrome	5.98e-06	4.2e-05	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—SLC2A1—epilepsy syndrome	5.96e-06	4.19e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—CXCL2—epilepsy syndrome	5.92e-06	4.16e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—CRH—epilepsy syndrome	5.92e-06	4.16e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—CCL3—epilepsy syndrome	5.92e-06	4.16e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—HSPB1—epilepsy syndrome	5.92e-06	4.16e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—OXT—epilepsy syndrome	5.92e-06	4.16e-05	CbGpPWpGaD
Mivacurium—CHRM2—GPCR downstream signaling—AGT—epilepsy syndrome	5.92e-06	4.16e-05	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—PLCB1—epilepsy syndrome	5.89e-06	4.14e-05	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—TH—epilepsy syndrome	5.87e-06	4.12e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—HSPB1—epilepsy syndrome	5.87e-06	4.12e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—CCL3—epilepsy syndrome	5.87e-06	4.12e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—CXCL2—epilepsy syndrome	5.87e-06	4.12e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—OXT—epilepsy syndrome	5.87e-06	4.12e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—CRH—epilepsy syndrome	5.87e-06	4.12e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—CCR5—epilepsy syndrome	5.84e-06	4.11e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—CCR5—epilepsy syndrome	5.79e-06	4.07e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—HTR2A—epilepsy syndrome	5.72e-06	4.02e-05	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—GPX1—epilepsy syndrome	5.69e-06	3.99e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—HTR2A—epilepsy syndrome	5.66e-06	3.98e-05	CbGpPWpGaD
Mivacurium—CHRM3—GPCR downstream signaling—PRKCB—epilepsy syndrome	5.52e-06	3.88e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—TSC1—epilepsy syndrome	5.51e-06	3.87e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—PTK2B—epilepsy syndrome	5.51e-06	3.87e-05	CbGpPWpGaD
Mivacurium—CHRM2—GPCR downstream signaling—PRKCB—epilepsy syndrome	5.47e-06	3.84e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—TSC1—epilepsy syndrome	5.45e-06	3.83e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—PTK2B—epilepsy syndrome	5.45e-06	3.83e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—AGT—epilepsy syndrome	5.43e-06	3.81e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—AGT—epilepsy syndrome	5.37e-06	3.78e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—CCR2—epilepsy syndrome	5.36e-06	3.76e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—NTRK2—epilepsy syndrome	5.36e-06	3.76e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—SST—epilepsy syndrome	5.36e-06	3.76e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—DUSP6—epilepsy syndrome	5.31e-06	3.73e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—CCR2—epilepsy syndrome	5.31e-06	3.73e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—SST—epilepsy syndrome	5.31e-06	3.73e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—NTRK2—epilepsy syndrome	5.31e-06	3.73e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—DUSP6—epilepsy syndrome	5.26e-06	3.7e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—ADRA2A—epilepsy syndrome	5.24e-06	3.68e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—PLAT—epilepsy syndrome	5.22e-06	3.67e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—ADRA2A—epilepsy syndrome	5.19e-06	3.65e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—PLAT—epilepsy syndrome	5.17e-06	3.63e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—CXCL12—epilepsy syndrome	5.04e-06	3.54e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—BDKRB2—epilepsy syndrome	5.04e-06	3.54e-05	CbGpPWpGaD
Mivacurium—CHRM3—GPCR downstream signaling—POMC—epilepsy syndrome	5.03e-06	3.53e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—PRKCB—epilepsy syndrome	5.01e-06	3.52e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—IL6ST—epilepsy syndrome	4.99e-06	3.51e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—CXCL12—epilepsy syndrome	4.99e-06	3.5e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—BDKRB2—epilepsy syndrome	4.99e-06	3.5e-05	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—AGT—epilepsy syndrome	4.99e-06	3.5e-05	CbGpPWpGaD
Mivacurium—CHRM2—GPCR downstream signaling—POMC—epilepsy syndrome	4.98e-06	3.5e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—PRKCB—epilepsy syndrome	4.97e-06	3.49e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—IL6ST—epilepsy syndrome	4.95e-06	3.47e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—JUNB—epilepsy syndrome	4.94e-06	3.47e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—CNR1—epilepsy syndrome	4.94e-06	3.47e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—PLCB1—epilepsy syndrome	4.93e-06	3.46e-05	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—HMOX1—epilepsy syndrome	4.9e-06	3.44e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—CNR1—epilepsy syndrome	4.9e-06	3.44e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—JUNB—epilepsy syndrome	4.9e-06	3.44e-05	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—APOE—epilepsy syndrome	4.89e-06	3.43e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—PLCB1—epilepsy syndrome	4.88e-06	3.43e-05	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—CAT—epilepsy syndrome	4.83e-06	3.4e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—HTR7—epilepsy syndrome	4.82e-06	3.39e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—HTR7—epilepsy syndrome	4.78e-06	3.36e-05	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—ABCB1—epilepsy syndrome	4.7e-06	3.3e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—HBEGF—epilepsy syndrome	4.68e-06	3.29e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—HBEGF—epilepsy syndrome	4.64e-06	3.26e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—AKT3—epilepsy syndrome	4.6e-06	3.23e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—POMC—epilepsy syndrome	4.57e-06	3.21e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—AKT3—epilepsy syndrome	4.55e-06	3.2e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—POMC—epilepsy syndrome	4.52e-06	3.18e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—ADAM10—epilepsy syndrome	4.49e-06	3.15e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—CCL2—epilepsy syndrome	4.47e-06	3.14e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—ADAM10—epilepsy syndrome	4.45e-06	3.12e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—CCL2—epilepsy syndrome	4.43e-06	3.11e-05	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—GPX1—epilepsy syndrome	4.37e-06	3.07e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—S100B—epilepsy syndrome	4.25e-06	2.98e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—S100B—epilepsy syndrome	4.2e-06	2.95e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—SOCS3—epilepsy syndrome	4.2e-06	2.95e-05	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—POMC—epilepsy syndrome	4.2e-06	2.95e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—CDC42—epilepsy syndrome	4.19e-06	2.95e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—SOCS3—epilepsy syndrome	4.16e-06	2.93e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—CDC42—epilepsy syndrome	4.15e-06	2.92e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—AVP—epilepsy syndrome	4.06e-06	2.85e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—AVP—epilepsy syndrome	4.02e-06	2.83e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—HES1—epilepsy syndrome	3.84e-06	2.7e-05	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—AGT—epilepsy syndrome	3.83e-06	2.69e-05	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—ALB—epilepsy syndrome	3.83e-06	2.69e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—HES1—epilepsy syndrome	3.8e-06	2.67e-05	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—APOE—epilepsy syndrome	3.76e-06	2.64e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—FYN—epilepsy syndrome	3.73e-06	2.62e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—H2AFX—epilepsy syndrome	3.72e-06	2.61e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—MEF2C—epilepsy syndrome	3.71e-06	2.61e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—FYN—epilepsy syndrome	3.7e-06	2.6e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—H2AFX—epilepsy syndrome	3.68e-06	2.59e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—MEF2C—epilepsy syndrome	3.68e-06	2.58e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—YWHAZ—epilepsy syndrome	3.59e-06	2.52e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—YWHAZ—epilepsy syndrome	3.55e-06	2.5e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—NGF—epilepsy syndrome	3.55e-06	2.49e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—NGF—epilepsy syndrome	3.51e-06	2.47e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—CCR5—epilepsy syndrome	3.45e-06	2.43e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—CCR5—epilepsy syndrome	3.42e-06	2.4e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—HTR2A—epilepsy syndrome	3.38e-06	2.37e-05	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—PTGS2—epilepsy syndrome	3.35e-06	2.35e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—HTR2A—epilepsy syndrome	3.35e-06	2.35e-05	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—POMC—epilepsy syndrome	3.23e-06	2.27e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—TSC2—epilepsy syndrome	3.21e-06	2.26e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—AGT—epilepsy syndrome	3.21e-06	2.25e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—TSC2—epilepsy syndrome	3.18e-06	2.23e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—AGT—epilepsy syndrome	3.17e-06	2.23e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—APOE—epilepsy syndrome	3.14e-06	2.21e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—APOE—epilepsy syndrome	3.11e-06	2.19e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—KDR—epilepsy syndrome	3.08e-06	2.16e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—KDR—epilepsy syndrome	3.05e-06	2.14e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—PRKCB—epilepsy syndrome	2.96e-06	2.08e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—IL6ST—epilepsy syndrome	2.95e-06	2.07e-05	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—ALB—epilepsy syndrome	2.94e-06	2.07e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—PRKCB—epilepsy syndrome	2.93e-06	2.06e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—IL6ST—epilepsy syndrome	2.92e-06	2.05e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—POMC—epilepsy syndrome	2.7e-06	1.9e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—POMC—epilepsy syndrome	2.67e-06	1.88e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—CCL2—epilepsy syndrome	2.64e-06	1.85e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—CCL2—epilepsy syndrome	2.61e-06	1.84e-05	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—PTGS2—epilepsy syndrome	2.57e-06	1.81e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—FGF2—epilepsy syndrome	2.39e-06	1.68e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—FGF2—epilepsy syndrome	2.36e-06	1.66e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—RELA—epilepsy syndrome	2.22e-06	1.56e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—RELA—epilepsy syndrome	2.19e-06	1.54e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—MTOR—epilepsy syndrome	2.17e-06	1.53e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—MTOR—epilepsy syndrome	2.15e-06	1.51e-05	CbGpPWpGaD
Mivacurium—CHRM3—GPCR downstream signaling—AKT1—epilepsy syndrome	2.02e-06	1.42e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—CASP3—epilepsy syndrome	2e-06	1.4e-05	CbGpPWpGaD
Mivacurium—CHRM2—GPCR downstream signaling—AKT1—epilepsy syndrome	2e-06	1.4e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—CASP3—epilepsy syndrome	1.98e-06	1.39e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—JUN—epilepsy syndrome	1.94e-06	1.36e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—JUN—epilepsy syndrome	1.92e-06	1.35e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—MMP9—epilepsy syndrome	1.89e-06	1.33e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—MMP9—epilepsy syndrome	1.87e-06	1.31e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling by GPCR—AKT1—epilepsy syndrome	1.83e-06	1.29e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling by GPCR—AKT1—epilepsy syndrome	1.81e-06	1.27e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—SRC—epilepsy syndrome	1.74e-06	1.22e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—SRC—epilepsy syndrome	1.72e-06	1.21e-05	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—VEGFA—epilepsy syndrome	1.7e-06	1.19e-05	CbGpPWpGaD
Mivacurium—BCHE—Metabolism—AKT1—epilepsy syndrome	1.68e-06	1.18e-05	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—VEGFA—epilepsy syndrome	1.68e-06	1.18e-05	CbGpPWpGaD
Mivacurium—CHRM3—Metabolism—AKT1—epilepsy syndrome	1.29e-06	9.09e-06	CbGpPWpGaD
Mivacurium—CHRM3—Signaling Pathways—AKT1—epilepsy syndrome	1.08e-06	7.6e-06	CbGpPWpGaD
Mivacurium—CHRM2—Signaling Pathways—AKT1—epilepsy syndrome	1.07e-06	7.53e-06	CbGpPWpGaD
